Literature DB >> 11225602

Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases.

D Falush1, E W Almqvist, R R Brinkmann, Y Iwasa, M R Hayden.   

Abstract

We describe a new approach for analysis of the epidemiology of progressive genetic disorders that quantifies the rate of progression of the disease in the population by measuring the mutational flow. The framework is applied to Huntington disease (HD), a dominant neurological disorder caused by the expansion of a CAG-trinucleotide sequence to >35 repeats. The disease is 100% penetrant in individuals with > or = 42 repeats. Measurement of the flow from disease alleles provides a minimum estimate of the flow in the whole population and implies that the new mutation rate for HD in each generation is > or = 10% of currently known cases (95% confidence limits 6%-14%). Analysis of the pattern of flow demonstrates systematic underascertainment for repeat lengths <44. Ascertainment falls to <50% for individuals with 40 repeats and to <5% for individuals with 36-38 repeats. Clinicians should not assume that HD is rare outside known pedigrees or that most cases have onset at age <50 years.

Entities:  

Mesh:

Year:  2001        PMID: 11225602      PMCID: PMC1235271          DOI: 10.1086/318193

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  25 in total

1.  Clustered microsatellite mutations in the pipefish Syngnathus typhle.

Authors:  A G Jones; G Rosenqvist; A Berglund; J C Avise
Journal:  Genetics       Date:  1999-07       Impact factor: 4.562

2.  Analysis of germline mutation spectra at the Huntington's disease locus supports a mitotic mutation mechanism.

Authors:  E P Leeflang; S Tavaré; P Marjoram; C O Neal; J Srinidhi; H MacFarlane; M E MacDonald; J F Gusella; M de Young; N S Wexler; N Arnheim
Journal:  Hum Mol Genet       Date:  1999-02       Impact factor: 6.150

Review 3.  Rethinking genotype and phenotype correlations in polyglutamine expansion disorders.

Authors:  S E Andrew; Y P Goldberg; M R Hayden
Journal:  Hum Mol Genet       Date:  1997-11       Impact factor: 6.150

4.  Late-onset Huntington's disease: a clinical and molecular study.

Authors:  C M James; G D Houlihan; R G Snell; J P Cheadle; P S Harper
Journal:  Age Ageing       Date:  1994-11       Impact factor: 10.668

5.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

6.  Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects.

Authors:  Y P Goldberg; B Kremer; S E Andrew; J Theilmann; R K Graham; F Squitieri; H Telenius; S Adam; A Sajoo; E Starr
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

7.  The mutation rate to Huntington's chorea.

Authors:  M Shaw; A Caro
Journal:  J Med Genet       Date:  1982-06       Impact factor: 6.318

Review 8.  Huntington disease: genetics and epidemiology.

Authors:  P M Conneally
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

Review 9.  The epidemiology of Huntington's disease.

Authors:  P S Harper
Journal:  Hum Genet       Date:  1992-06       Impact factor: 4.132

10.  Evidence for specific cognitive deficits in preclinical Huntington's disease.

Authors:  A D Lawrence; J R Hodges; A E Rosser; A Kershaw; C ffrench-Constant; D C Rubinsztein; T W Robbins; B J Sahakian
Journal:  Brain       Date:  1998-07       Impact factor: 13.501

View more
  22 in total

1.  Incidence and mutation rates of Huntington's disease in Spain: experience of 9 years of direct genetic testing.

Authors:  M A Ramos-Arroyo; S Moreno; A Valiente
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

2.  Haplotype background, repeat length evolution, and Huntington's disease.

Authors:  Daniel Falush
Journal:  Am J Hum Genet       Date:  2009-12       Impact factor: 11.025

Review 3.  CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches.

Authors:  Douglas R Langbehn; Michael R Hayden; Jane S Paulsen
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

4.  [Huntington's chorea mimicking adult attention deficit hyperactivity disorder].

Authors:  M Kraemer; S Haertig; A Hill; J Uekermann; J Wiltfang; B Kis
Journal:  Nervenarzt       Date:  2011-03       Impact factor: 1.214

5.  Transfer of genetic therapy across human populations: molecular targets for increasing patient coverage in repeat expansion diseases.

Authors:  Miguel A Varela; Helen J Curtis; Andrew G L Douglas; Suzan M Hammond; Aisling J O'Loughlin; Maria J Sobrido; Janine Scholefield; Matthew J A Wood
Journal:  Eur J Hum Genet       Date:  2015-05-20       Impact factor: 4.246

6.  Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

Authors:  Annie Killoran; Kevin M Biglan; Joseph Jankovic; Shirley Eberly; Elise Kayson; David Oakes; Anne B Young; Ira Shoulson
Journal:  Neurology       Date:  2013-04-26       Impact factor: 9.910

7.  Long-term monitoring of the mortality trend of Huntington's disease in Austria.

Authors:  Eva Ekestern; Gustav Lebhart
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

8.  "Grasping the grey": patient understanding and interpretation of an intermediate allele predictive test result for Huntington disease.

Authors:  A Semaka; L G Balneaves; M R Hayden
Journal:  J Genet Couns       Date:  2012-08-18       Impact factor: 2.537

9.  Predicting Disease Onset from Mutation Status Using Proband and Relative Data with Applications to Huntington's Disease.

Authors:  Tianle Chen; Yuanjia Wang; Yanyuan Ma; Karen Marder; Douglas R Langbehn
Journal:  J Probab Stat       Date:  2012-01-01

10.  Huntington disease reduced penetrance alleles occur at high frequency in the general population.

Authors:  Chris Kay; Jennifer A Collins; Zosia Miedzybrodzka; Steven J Madore; Erynn S Gordon; Norman Gerry; Mark Davidson; Ramy A Slama; Michael R Hayden
Journal:  Neurology       Date:  2016-06-22       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.